deltatrials
Completed PHASE1 INTERVENTIONAL 3-arm NCT04787991

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (REVOLUTION)

A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)

Sponsor: Akamis Bio

Conditions Metastatic Pancreatic Adenocarcinoma
Interventions Gemcitabine (gem) (Cohort A, B and C) Hydroxychloroquine (HCQ) (Cohort B) Ipilimumab (Cohort A, B and C) NG350A (Cohort C) Nab-paclitaxel (nP) (Cohort A, B and C) Nivolumab (Cohort A)
Updated 17 times since 2021 Last updated: Oct 29, 2025 Started: Aug 9, 2021 Primary completion: Nov 12, 2024 Completion: Jul 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic Pancreatic Adenocarcinoma and is currently completed. Akamis Bio leads this study, which shows 17 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jul 2022 · 7 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Sep 2023 · 7 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

17 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  2. Sep 2024 — Nov 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Nov 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Sep 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Feb 2023 — Sep 2023 [monthly]

    Recruiting PHASE1

  3. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  4. Nov 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  6. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  7. Dec 2021 — Jul 2022 [monthly]

    Recruiting PHASE1

  8. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  9. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  10. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1

  11. May 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE1

  12. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Akamis Bio
  • Bristol-Myers Squibb
  • Cancer Insight, LLC
  • Cancer Research Institute, New York City
Data source: Cancer Insight, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations